796 related articles for article (PubMed ID: 17536186)
21. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.
Arbel-Ornath M; Becker M; Rabinovich-Toidman P; Gartner M; Solomon B
J Alzheimers Dis; 2010; 22(2):469-82. PubMed ID: 20847413
[TBL] [Abstract][Full Text] [Related]
24. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.
Sohn JH; So JO; Kim H; Nam EJ; Ha HJ; Kim YH; Mook-Jung I
Biochem Biophys Res Commun; 2007 Sep; 361(3):800-4. PubMed ID: 17678618
[TBL] [Abstract][Full Text] [Related]
25. Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice.
Philipson O; Lannfelt L; Nilsson LN
FEBS Lett; 2009 Sep; 583(18):3021-6. PubMed ID: 19683527
[TBL] [Abstract][Full Text] [Related]
26. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
[TBL] [Abstract][Full Text] [Related]
28. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice.
Seabrook TJ; Jiang L; Maier M; Lemere CA
Glia; 2006 May; 53(7):776-82. PubMed ID: 16534778
[TBL] [Abstract][Full Text] [Related]
29. A novel beta-site amyloid precursor protein cleaving enzyme (BACE) isoform regulated by nonsense-mediated mRNA decay and proteasome-dependent degradation.
Tanahashi H; Tabira T
Neurosci Lett; 2007 Nov; 428(2-3):103-8. PubMed ID: 17961921
[TBL] [Abstract][Full Text] [Related]
30. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease.
Wang YJ; Gao CY; Yang M; Liu XH; Sun Y; Pollard A; Dong XY; Wu XB; Zhong JH; Zhou HD; Zhou XF
Brain Behav Immun; 2010 Nov; 24(8):1281-93. PubMed ID: 20595065
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP.
Li L; Zhang X; Yang D; Luo G; Chen S; Le W
Neurobiol Aging; 2009 Jul; 30(7):1091-8. PubMed ID: 18063223
[TBL] [Abstract][Full Text] [Related]
33. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
Jensen MT; Mottin MD; Cracchiolo JR; Leighty RE; Arendash GW
Neuroscience; 2005; 130(3):667-84. PubMed ID: 15590151
[TBL] [Abstract][Full Text] [Related]
34. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice.
Tong XK; Nicolakakis N; Fernandes P; Ongali B; Brouillette J; Quirion R; Hamel E
Neurobiol Dis; 2009 Sep; 35(3):406-14. PubMed ID: 19524673
[TBL] [Abstract][Full Text] [Related]
35. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage.
Burbach GJ; Vlachos A; Ghebremedhin E; Del Turco D; Coomaraswamy J; Staufenbiel M; Jucker M; Deller T
Neurobiol Aging; 2007 Feb; 28(2):202-12. PubMed ID: 16427722
[TBL] [Abstract][Full Text] [Related]
36. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease.
George AJ; Holsinger RM; McLean CA; Laughton KM; Beyreuther K; Evin G; Masters CL; Li QX
Neurobiol Dis; 2004 Jun; 16(1):124-32. PubMed ID: 15207269
[TBL] [Abstract][Full Text] [Related]
37. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration.
Yoon SY; Choi JE; Yoon JH; Huh JW; Kim DH
Neurobiol Dis; 2006 May; 22(2):435-44. PubMed ID: 16480887
[TBL] [Abstract][Full Text] [Related]
38. Caffeine and coffee as therapeutics against Alzheimer's disease.
Arendash GW; Cao C
J Alzheimers Dis; 2010; 20 Suppl 1():S117-26. PubMed ID: 20182037
[TBL] [Abstract][Full Text] [Related]
39. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase.
Sahlin C; Lord A; Magnusson K; Englund H; Almeida CG; Greengard P; Nyberg F; Gouras GK; Lannfelt L; Nilsson LN
J Neurochem; 2007 May; 101(3):854-62. PubMed ID: 17448150
[TBL] [Abstract][Full Text] [Related]
40. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
Olcese JM; Cao C; Mori T; Mamcarz MB; Maxwell A; Runfeldt MJ; Wang L; Zhang C; Lin X; Zhang G; Arendash GW
J Pineal Res; 2009 Aug; 47(1):82-96. PubMed ID: 19538338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
